Fish oils ã¢â‚¬â€œ adjuvant therapy in chronic heart failure?

European Journal of Preventive Cardiology

Volumn 11, Issue 4, 2004, Pages 267-274

  Witte, Klaus K a ^a   Clark, Andrew L ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

arachadonic acid; chronic heart failure; docosahexanoic acid; eicosapentanoic acid

Indexed keywords

CYTOKINE; ENDOTHELIN 1; FISH OIL; LIPID; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BLOOD PRESSURE; CACHEXIA; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; FATTY ACID METABOLISM; HEART ARRHYTHMIA; HEART FAILURE; HEMODYNAMICS; HEMOSTASIS; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; PRIORITY JOURNAL; REVIEW; SUPPLEMENTATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARRHYTHMIA; BLOOD PRESSURE; CACHEXIA; CHEMOTHERAPY, ADJUVANT; CHRONIC DISEASE; FATTY ACIDS; FISH OILS; HEART FAILURE, CONGESTIVE; HEMOSTASIS; HUMANS; IMMUNOLOGIC FACTORS; MYOCARDIAL ISCHEMIA;

EID: 4344629692     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000136728.27524.f5     Document Type: Article

References (144)

1. Cowie MR, Mosterd A, Wood DA. The epidemiology of heart failure. Eur Heart J 1997; 18: 208–225.
2. Braunwald E. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337: 1360–1369.
3. Brown A, Cleland JGF. Influence of concomitant disease on patterns of hospitalisations in patients with heart failure from Scottish hospitals in 1995. Eur Heart J 1998; 19: 1063–1069.
4. Cleland JGF, Swedberg K, Poole-Wilson PA. Successes and failures of current treatment of heart failure. Lancet 1998; 352(Suppl 1):19–28.
5. Cleland JG, Thygesen K, Uretsky BF, Armstrong P, Horowitz JD, Massie B, et al. ATLAS investigators. Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. Eur Heart J 2001; 22: 1601–1612.
6. McMurray J, McDonagh T, Morrison CE, Dargie HJ. Trends in hospitalisation for heart failure in Scotland 1980–1990. Eur Heart J 1993; 14: 1158–1162.
7. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. JAMA 1989; 262: 907–913.
8. Sinclair HM. Deficiency of essential fatty acids and atherosclerosis. Lancet 1956; i: 381–383.
9. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447–455.
10. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial re-infarction: Diet and Reinfarction Trial (DART). Lancet 1989; ii: 757–761.
11. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the Gruppo Italiano per lo Stuio deela Sopravivenza nell'Infarcto Miocardico (GISSI)-Prevenzione. Circulation 2002; 105: 1897–1903.
12. Wigmore SJ, Ross JA, Falconer JS, Plester CE, Tisdale MJ, Carter DC, Fearon KC. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. Nutrition 1996; 12(Suppl 1): S27–S30.
13. Barber MD. Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation. Nutrition 2001; 17: 751–755.
14. Simopoulos AP. v-3 Fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991; 54: 438–463.
15. Bang HO, Dyergerg J, Sinclair HM. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980; 33: 2657–2661.
16. Hrelia S, Lopez Jimenez JA, Bordoni A, Nvarro SZ, Horrobin DF, Rossi CA, Biagi PL. Essential fatty acid metabolism in cultured rat cardiomyocytes in response to either N-6 or N-3 fatty acid supplementation. Biochem Biophys Res Commun 1995; 216: 11–19.
17. Lands WEM, Morris A, Libelt B. Quantitative effects of dietary polyunsaturated fats on the composition of fatty acids in rat tissues. Lipids 1990; 25: 505–516.
18. Lands WEM, Libelt B, Morris A, et al. Maintenance of lower pro-portions of (n-6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n-3) fatty acids. Biochim Biophys Acta 1992; 1180: 147–162.
19. Cleland LG, Gibson RA, Neumann MA, Hamazaki T, Akimoto K, James MJ. Dietary (n-29) eicosatrienoic acid from a cultured fungus inhibits leukotriene B 4 synthesis in rats and the effect is modified by dietary linoleic acid. J Nutr 1996; 126: 1534–1540.
20. Cleland LG, James MJ, Neumann MA, D'Angelo M, Gibson RA. Linoleate inhibits EPA incorporation from dietary fish-oil supplements in human subjects. Am J Clin Nutr 1992; 55: 395–399.
21. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88: 523–533.
22. Mori TA, Bao DQ, Burke V, Puddey IB, Beilin LJ. Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans. Hypertension 1999; 34: 253–260.
23. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20: 1493–1499.
24. Chin JP. Marine oils and cardiovascular reactivity. Prostaglandins Leukot Essent Fatty Acids 1994; 50: 211–222.
25. Engler MB, Engler MM. Docosahexaenoic acid-induced vasorelaxation in hypertensive rats: mechanisms of action. Biol Res Nurs 2000; 2: 85–95.
26. Bayorh MA, McGee L, Feuerstein G. Acute and chronic effects of eicosapentaenoic acid (EPA) on the cardiovascular system. Res Commun Chem Pathol Pharmacol 1989; 66: 355–374.
27. Engler MM, Engler MB, Pierson DM, Molteni LB, Molteni A. Effects of docosahexaenoic acid on vascular pathology and reactivity in hypertension. Exp Biol Med (Maywood) 2003; 228: 299–307.
28. Cobiac L, Nestel PJ, Wing LM, Howe PR. A low-sodium diet supplemented with fish oil lowers blood pressure in the elderly. J Hypertens 1992; 10: 87–92.
29. Kenny D. The paradoxical effects of dietary fish oil on blood pressure. Med Hypotheses 1992; 37: 97–99.
30. Triboulot C, Hichami A, Denys A, Khan N.A. Dietary (n-3) polyunsaturated fatty acids exert antihypertensive effects by modulating calcium signaling in T cells of rats. J Nutr 2001; 131: 2364–2369.
31. Shimokawa H, Lam JY, Chesebro JH, Bowie EJ, Vanhoutte PM. Effects of dietary supplementation with cod-liver oil on endotheliumdependent responses in porcine coronary arteries. Circulation 1987; 76: 898–905.
32. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998; 21: 494–500.
33. Montori VM, Farmer A, Wollan PC, Dinneen SF. Fish oil supplementation in type 2 diabetes: a quantitative systematic review. Diabetes Care 2000; 23: 1407–1415.
34. Nordoy A, Hansen JB, Brox J. The effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipidemia in patients with combined hyperlipidemia. Nutr Metab Cardiovasc Dis 2001; 11: 7–16.
35. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002; 76: 1007–1015.
36. Friday KE, Childs MT, Tsunehara CH, Fujimoto WY, Bierman EL, Ensinck JW. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes. Diabetes Care 1989; 12: 276–281.
37. Glauber H, Wallace P, Griver K, Brechtel G. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus. Ann Intern Med 1988; 108: 663–668.
38. Hu FB, Eunyoung C, Rexrode KM, Albert CM, Manson JE. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003; 107: 1852–1857.
39. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake and the risk of coronary disease among men. N Engl J Med 1995; 332: 977–982.
40. Albert CM, Hennekens CH, O'Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23–28.
41. Kromhout D, Bosschieter ER, de Lezenne CC. The inverse relationship between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312: 1205–1209.
42. Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997; 336: 1046–1053.
43. Dolecek TA. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial. Proc Soc Exp Biol Med 1992; 200: 177–182.
44. Rodriguez BL, Sharp DS, Abbott RD, et al. Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers: The Honolulu Heart Program. Circulation 1996; 94: 952–956.
45. Ness AR, Hughes J, Elwood PC, Whitley E, Smith GD, Burr ML. The long-term effect of dietary advice in men with coronary disease: follow-up of the Diet and Reinfarction trial (DART). Eur J Clin Nutr 2002; 56: 512–518.
46. Pepe S, McLennan PL. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function. Circulation 2002; 105: 2303–2308.
47. Mehta JL, Lopez LM, Lawson D, Wargovich TJ, Williams LL. Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease. Effects on indices of platelet and neutrophil function and exercise performance. Am J Med 1988; 84: 45–52.
48. Vandongen R, Mori TA, Burke V, Beilin LJ, Morris J, Ritchie J. Effects on blood pressure of omega 3 fats in subjects at increased risk of cardiovascular disease. Hypertension 1993; 22: 371–379.
49. Grimsgaard S, Bønaa KH, Hansen J-B, Myhre ESP. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans 1–3. Am J Clin Nutr 1998; 68: 52–59.
50. McLennan PL, Barnden LR, Bridle TM, Abeywardena MY, Charnock JS. Dietary fat modulation of left ventricular ejection fraction in the marmoset due to enhanced filling. Cardiovasc Res 1992; 26: 871–877.
51. Ventura HO, Milani RV, Lavie CJ, et al. Cyclosporine-induced hypertension. Efficacy of omega-3 fatty acids in patients after cardiac transplantation. Circulation 1993; 88: II281–II285.
52. Nishimura M, Nanbu A, Komori T, Ohtsuka K, Takahashi H, Yoshimura M. Eicosapentaenoic acid stimulates nitric oxide production and decreases cardiac noradrenaline in diabetic rats. Clin Exp Pharmacol Physiol 2000; 27: 618–624.
53. Hayashi M, Nasa Y, Tanonaka K, Sasaki H, Miyake R, Hayashi J, Takeo S. The effects of long-term treatment with eicosapentaenoic acid and docosahexaenoic acid on hypoxia/rexoygenation injury of isolated cardiac cells in adult rats. J Mol Cell Cardiol 1995; 27: 2031–2041.
54. Otsuji S, Shibata N, Hirota H, Akagami H, Wada A. Highly purified eicosapentaenoic acid attenuates tissue damage in experimental myocardial infarction. Jpn Circ J 1993; 57: 335–343.
55. Zhu BQ, Sievers RE, Sun YP, Morse-Fisher N, Parmley WW, Wolfe CL. Is the reduction of myocardial infarct size by dietary fish oil the result of altered platelet function? Am Heart J 1994; 127: 744–755.
56. Dusing R, Struck A, Gobel BO, Weisser B, Vetter H. Effects of n-3 fatty acids on renal function and renal prostaglandin E metabolism. Kidney Int 1990; 38: 315–319.
57. Holm T, Andreassen AK, Aukrust P, Andersen K, Geiran OR, Kjekshus J, et al. Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients. Eur Heart J 2001; 22: 428–436.
58. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236–241.
59. Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20: 683–693.
60. Anker SD, Clark AL, Kemp M, et al. Tumour necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997; 30: 997–1001.
61. Zhao SP, Zeng LH. Elevated plasma levels of tumour necrosis factor in chronic heart failure with cachexia. Int J Cardiol 1997; 58: 257–261.
62. Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996; 3: 243–249.
63. Berkowitz DE, Brown D, Lee KM. Endotoxin-induced alteration in the expression of leptin and beta-3 adrenergic receptor in adipose tissue. Am J Physiol 1998; 274: 992–997.
64. Mantzoros CS, Moschos S, Avramopoulos I. Leptin concentrations in relation to body mass index and the tumour necrosis factor-alpha system in humans. J Clin Endocrinol Metab 1997; 82: 3408–3413.
65. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor a in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151–160.
66. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989; 44: 153–205.
67. Pakala R, Pakala R, Sheng WL, Benedict CR. Vascular smooth muscle cells preloaded with eicosapentaenoic acid and docosahexaenoic acid fail to respond to serotonin stimulation. Atherosclerosis 2000; 153: 47–57.
68. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor-α and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996; 63: 116–122.
69. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 2003; 100: 1751–1756.
70. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265–271.
71. Meydani S, Endres S, Woods MM, et al. Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between younger and older women. J Nutr 1991; 121: 547–555.
72. Kremer JM, Lawrence DA, Jubiz W, et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 810–820.
73. Lo CJ, Chiu KC, Fu M, Lo R, Helton S. Fish oil decreases macrophage tumor necrosis factor gene transcription by altering the NF kappa B activity. J Surg Res 1999; 82: 216–221.
74. Khalfoun B, Thibault F, Watier H, Bardos P, Lebranchu Y. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv Exp Med Biol 1997; 400B: 589–597.
75. Shimizu T, Iwamoto T, Itou S, Iwata N, Endo T, Takasaki M. Effect of ethyl icosapentaenoate (EPA) on the concentration of tumor necrosis factor (TNF) and interleukin-1 (IL-1) in the carotid artery of cuff-sheathed rabbit models. J Atheroscler Thromb 2001; 8: 45–49.
76. Hawkes JS, James MJ, Cleland LG. Biological activity of prostaglandin E 3 with regard to oedema formation in mice. Agents Actions 1992; 35: 85–87.
77. Hawkes JS, James MJ, Cleland LG. Separation and quantification of PGE 3 following derivatization with panacyl bromide by high pressure liquid chromatography with fluorometric detection. Prostaglandins 1991; 42: 355–368.
78. James MJ, Cleland LG, Gibson RA, Hawkes JS. Interaction between fish and vegetable oils in relation to rat leucocyte leukotriene production. J Nutr 1991; 121: 631–637.
79. Goldman DW, Pickett WC, Goetzl EJ. Human neutrophil chemotactic and degranulating activities of leukotriene B 5 (LTB 5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun 1983; 117: 282–288.
80. Miles EA, Allen E, Calder PC. In vitro effects of eicosanoids derived from different 20-carbon Fatty acids on production of monocyte-derived cytokines in human whole blood cultures. Cytokine 2002; 20: 215–223.
81. Anderson M, Fritsche KL. (n-3) Fatty acids and infectious disease resistance. J Nutr 2002; 132: 3566–3576.
82. Switzer KC, McMurray DN, Morris JS, Chapkin RS. (n-3) Polyunsaturated fatty acids promote activation-induced cell death in murine T lymphocytes. J Nutr 2003; 133: 496–503.
83. Bechoua S, Dubois M, Vericel E, Chapuy P, Lagarde M, Prigent AF. Influence of very low dietary intake of marine oil on some functional aspects of immune cells in healthy elderly people. Br J Nutr 2003; 89: 523–531.
84. Wallace FA, Miles EA, Calder PC. Comparison of the effects of linseed oil and different doses of fish oil on mononuclear cell function in healthy human subjects. Br J Nutr 2003; 89: 679–689.
85. Kew S, Banerjee T, Minihane AM, Finnegan YE, Muggli R, Albers R, et al. Lack of effect of foods enriched with plant- or marine-derived n-3 fatty acids on human immune function. Am J Clin Nutr 2003; 77: 1287–1295.
86. Thies F, Miles EA, Nebe-von-Caron G, Powell JR, Hurst TL, Newsholme EA, Calder PC. Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. Lipids 2001; 36: 1183–1193.
87. Caughey GE, Pouliot M, Cleland LG, James MJ. Regulation of tumor necrosis factor alpha and interleukin-1 beta synthesis by thromboxane A 2 in non-adherent human monocytes. J Immunol 1997; 158: 351–358.
88. Caughey GE, Mantzioris E, Gibson RA, Cleland LG, James MJ. The effect on human tumor necrosis factor-α and interleukin 1β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996; 63: 116–122.
89. von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985; 76: 2446–2450.
90. Nieuwenhuys CM, Feijge MA, Offermans RF, Kester AD, Hornstra G, Heemskerk JW. Modulation of rat platelet activation by vessel wall-derived prostaglandin and platelet-derived thromboxane: effects of dietary fish oil on thromboxane-prostaglandin balance. Atherosclerosis 2001; 154: 355–366.
91. Mezzano D, Kosiel K, Martinez C, Cuevas A, Panes O, Aranda E, et al. Cardiovascular risk factors in vegetarians. Normalization of hyperhomocysteinemia with vitamin B(12) and reduction of platelet aggregation with n-3 fatty acids. Thromb Res 2000; 100: 153–160.
92. Woodman RJ, Mori TA, Burke V, Puddey IB, Barden A, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003; 166: 85–93.
93. Svaneborg N, Kristensen SD, Hansen LM, Bullow I, Husted SE, Schmidt EB. The acute and short-time effect of supplementation with the combination of n-3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids. Thromb Res 2002; 105: 311–316.
94. Knapp HR. Dietary fatty acids in human thrombosis and hemostasis. Am J Clin Nutr 1997; 65(5 Suppl):1687S–1698S.
95. Kim DN, Eastman A, Baker JE, Mastrangelo A, Sethi S, Ross JS, et al. Fish oil, atherogenesis, and thrombogenesis. Ann NY Acad Sci 1995; 748: 474–480.
96. Andreassen AK, Nordoy I, Simonsen S, Ueland T, Muller F, Froland SS, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998; 81: 604–608.
97. Tousoulis D, Homaei H, Ahmed N, Asimakopoulos G, Zouridakis E, Toutouzas P, Davies GJ. Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy. Am Heart J 2001; 141: 277–280.
98. Mayer K, Merfels M, Muhly-Reinholz M, Gokorsch S, Rosseau S, Lohmeyer J, et al. Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol 2002; 283: H811–818.
99. Cohn JN. Is there a role for endothelin in the natural history of heart failure? Circulation 1996; 94: 604–606.
100. Kohno M, Ohmori K, Wada Y, Kondo I, Noma T, Fujita N, et al. Inhibition by eicosapentaenoic acid of oxidized-LDL- and lysophosphatidylcholineinduced human coronary artery smooth muscle cell production of endothelin. J Vasc Res 2001; 38: 379–388.
101. Schwengel RH, Gottlieb SS, Fisher ML. Protein-energy malnutrition in patients with ischaemic and non-ischaemic dilated cardiomyopathy and congestive heart failure. Am J Cardiol 1994; 73: 908–910.
102. Anker S, Ponikowski P, Varney S, et al. Wasting as an independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050–1053.
103. Carr JG, Stevenson LW, Walden JA, Heber D. Prevalence and haemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1989; 63: 709–713.
104. Mancini DM, Walter G, Reichnek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992; 85: 1364–1373.
105. Pittman JG, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med 1964; 271: 453–460.
106. Berry C, Clark AL. Catabolism in chronic heart failure. Eur Heart J 2000; 21: 521–532.
107. Anand IS, Ferrari R, Kalra GS, et al. Edema of cardiac origin. Studies of body water and sodium, renal function, haemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989; 80: 299–305.
108. Anker SD, Chua T, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526–534.
109. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999; 81: 80–86.
110. Whitehouse AS, Tisdale MJ. Downregulation of ubiquitin-dependent proteolysis by eicosapentaenoic acid in acute starvation. Biochem Biophys Res Commun 2001; 285: 598–602.
111. Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer 1997; 76: 1035–1040.
112. Price SA, Tisdale MJ. Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. Cancer Res 1998; 58: 4827–4831.
113. Cleland JG, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999; 1: 41–45.
114. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002; 346: 1113–1118.
115. McLennan PL, Abeywardena MY, Charnock JS. Influence of dietary lipids on arrhythmias and infarction after coronary artery ligation in rats. Can J Physiol Pharmacol 1985; 63: 1411–1417.
116. Charnock JS. Dietary fats and cardiac arrhythmia in primates. Nutrition 1994; 10: 161–169.
117. Hock CE, Beck LD, Bodine LC, Reibel DK. Influence of dietary n-3 fatty acids on myocardial ischemia and reperfusion. Am J Physiol 1990; 259: H1518–H1526.
118. Kang JX, Leaf A. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proc Natl Acad Sci USA 1994; 91: 9886–9890.
119. Kang JX, Leaf A. Prevention and termination of the beta-adrenergic agonist-induced arrhythmias by free polyunsaturated fatty acids in neonatal rat cardiac myocytes. Biochem Biophys Res Commun 1995; 208: 629–636.
120. Kang JX, Leaf A. Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. Eur J Pharmacol 1996; 297: 97–106.
121. Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids. Proc Natl Acad Sci USA 1994; 91: 4427–4430.
122. Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 2000; 71: 202S–207S.
123. Grynberg A, Fournier A, Sergiel JP, Athias P. Effect of docosahexaenoic acid and eicosapentaenoic acid in the phospholipids of rat heart muscle cells on adrenoceptor responsiveness and mechanism. J Mol Cell Cardiol 1995; 27: 2507–2520.
124. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454–1459.
125. Christensen JH, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K, et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 1997; 79: 1670–1673.
126. Sellmayer A, Witzgall H, Lorenz RL, Weber PC. Effects of dietary fish oil on ventricular premature complexes. Am J Cardiol 1995; 76: 974–977.
127. Christensen JH, Gustenhoff P, Korup E, et al. Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. BMJ 1996; 312: 677–678.
128. Villa B, Calabresi L, Chiesa G, Rise P, Galli C, Sirtori C. Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease. Pharmacol Res 2002; 45: 475.
129. Siscovick DS, Raghunathan TE, King I, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274: 1363–1367.
130. Xiao YF, Kang JX, Morgan JP, Leaf A. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1995; 92: 1100–1104.
131. Kang JX, Xiao YF, Leaf A. Free, long-chain, polyunsaturated fatty acids reduce membrane electrical excitability in neonatal rat cardiac myocytes. Proc Natl Acad Sci USA 1995; 92: 3997–4001.
132. McLennan PL, Bridle TM, Abeywardena MY, Charnock JS. Dietary lipid modulation of ventricular fibrillation threshold in the marmoset monkey. Am Heart J 1992; 123: 1555–1561.
133. Billman GE, Hallaq H, Leaf A. Prevention of ischemia-induced ventricular fibrillation by omega 3 fatty acids. Proc Natl Acad Sci USA 1994; 91: 4427–4430.
134. McLennan PL. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rats. Am J Clin Nutr 1993; 57: 207–212.
135. Billman GE, Kang JX, Leaf A. Prevention of sudden cardiac death by dietary pure omega-3 polyunsaturated fatty acids in dogs. Circulation 1999; 99: 2452–2457.
136. Burr M, Gilbert JF, Holliday RM, Elwood PC, Fehily AM, Rogers S, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 334: 757–761.
137. de Logeril M, Renaud S, Mamelle N, Salen P, Martin J-L, Monjaud I, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454–1459.
138. Siscovick DS, Raghunathan TE, King I, Weinmann S, Wicklund KG, Albright J, et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. J Am Med Assoc 1995; 274: 1363–1367.
139. Kinoshita I, Itoh K, Nishida-Nakai M, Hirota H, Otsuji S, Shibata N. Antiarrhythmic effects of eicosapentaenoic acid during myocardial infarction–enhanced cardiac microsomal (Ca2+-Mg2+)-ATPase activity. Jpn Circ J 1994; 58: 903–912.
140. Taffet GE, Pham TT, Bick DL, Entman ML, Pownall HJ, Bick RJ. The calcium uptake of the rat heart sarcoplasmic reticulum is altered by dietary lipid. J Membr Biol 1993; 131: 35–42.
141. Cleland JGF, Freemantle N, Kaye G, Nasir M, Velavan P, Lalukota K, et al. Clinical trials update from the American Heart Association meeting: Omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Fail 2004; 6: 109–115.
142. Freeman LM, Rush JE, Kehayias JJ, Ross JN Jr, Meydani SN, Brown DJ, et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med 1998; 12: 440–448.
143. Yusuf S, Pepine CJ, Garces C. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173–1178.
144. Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk 1997; 4: 385–391.